ABVC BioPharma, Inc. (ABVC)Healthcare | Biotechnology | Fremont, United States | NasdaqCM
0.98 USD
-0.01
(-1.071%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 0.98 |
Hot Take ↕ | Oct. 10, 2026, 6:34 a.m. EDT
The long-term outlook is dire due to a catastrophic nine-year price collapse of nearly 99%, driven by seven consecutive years of negative annual returns. Despite a massive 547% rebound in the most recent fiscal year, the company remains fundamentally broken with negative earnings, a negative forward P/E, and a precarious balance sheet where debt significantly outweighs equity. The recent spin-off of BioKey and conversion of notes suggest a desperate restructuring effort rather than a turnaround, leaving the core business exposed to high failure risk. On the short end, the technical picture is weak; the stock trades well below its 200-day moving average, and the statistical forecast models a slight downward drift over the next 45 days. Crucially, the options market confirms this pessimism, with traders aggressively buying deep out-of-the-money puts while offering almost no call liquidity, signaling an expectation of continued volatility and decline. With no dividend to provide income and a history of eroding shareholder value, this security offers no compelling investment case. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.093172 |
| AutoTheta | 0.105839 |
| AutoETS | 0.106790 |
| AutoARIMA | 0.244078 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.523 |
| Excess Kurtosis | -0.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.533 |
| Market Cap | 26,133,892 |
| Forward P/E | -2.23 |
| Beta | 0.51 |
| Previous Name | American BriVision (Holding) Corporation |
| Website | https://www.abvcpharma.com |
As of Oct. 10, 2026, 6:34 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in deep out-of-the-money puts (strikes up to 5x current price) relative to negligible call volume. This indicates a strong consensus among option buyers that the stock faces severe further depreciation rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.66206896 |
| Address1 | 44,370 Old Warm Springs Boulevard |
| All Time High | 7,165,605.0 |
| All Time Low | 0.343949 |
| Ask | 1.31 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 89,610 |
| Average Daily Volume3 Month | 108,842 |
| Average Volume | 108,842 |
| Average Volume10Days | 89,610 |
| Beta | 0.51 |
| Bid | 0.756 |
| Bid Size | 2 |
| Book Value | 0.404 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.979 |
| Current Ratio | 0.072 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.0182 |
| Day Low | 0.96 |
| Debt To Equity | 23.533 |
| Display Name | ABVC BioPharma |
| Dividend Date | 1,557,273,600 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -6,491,358 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.645 |
| Enterprise Value | 30,154,700 |
| Eps Forward | -0.44 |
| Eps Trailing Twelve Months | -0.3 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.98074 |
| Fifty Day Average Change | -0.0017400384 |
| Fifty Day Average Change Percent | -0.0017742097 |
| Fifty Two Week Change Percent | -66.206894 |
| Fifty Two Week High | 3.07 |
| Fifty Two Week High Change | -2.091 |
| Fifty Two Week High Change Percent | -0.6811075 |
| Fifty Two Week Low | 0.707 |
| Fifty Two Week Low Change | 0.27199996 |
| Fifty Two Week Low Change Percent | 0.3847241 |
| Fifty Two Week Range | 0.707 - 3.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,100,097,000,000 |
| Float Shares | 21,095,690 |
| Forward Eps | -0.44 |
| Forward P E | -2.225 |
| Free Cashflow | 1,563,662 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Fullday Change | -0.01060003 |
| Fullday Change Percent | -1.0711429 |
| Fullday Price | 0.979 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18087 |
| Held Percent Institutions | 0.04083 |
| Implied Shares Outstanding | 26,694,476 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,690,243,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. |
| Long Name | ABVC BioPharma, Inc. |
| Market | us_market |
| Market Cap | 26,133,892 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_325748154 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -7,106,633 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 30,385,976 |
| Open | 1.0 |
| Operating Cashflow | -2,690,948 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 668 0881 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.979 |
| Post Market Time | 1,791,923,234 |
| Prev Name | American BriVision (Holding) Corporation |
| Previous Close | 0.9896 |
| Price Hint | 4 |
| Price To Book | 2.4232671 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.023 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0106 |
| Regular Market Change Percent | -1.07114 |
| Regular Market Day High | 1.0182 |
| Regular Market Day Low | 0.96 |
| Regular Market Day Range | 0.96 - 1.0182 |
| Regular Market Open | 1.0 |
| Regular Market Previous Close | 0.9896 |
| Regular Market Price | 0.979 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 119,962 |
| Return On Assets | -0.22850001 |
| Return On Equity | -0.69858 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 26,694,476 |
| Shares Percent Shares Out | 0.0184 |
| Shares Short | 490,291 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 525,025 |
| Short Name | ABVC Biopharma, Inc. |
| Short Percent Of Float | 0.0224 |
| Short Ratio | 3.64 |
| Source Interval | 15 |
| State | CA |
| Symbol | ABVC |
| Total Cash | 94,364 |
| Total Cash Per Share | 0.004 |
| Total Debt | 2,887,361 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.342625 |
| Two Hundred Day Average Change | -0.36362505 |
| Two Hundred Day Average Change Percent | -0.27083144 |
| Type Disp | Equity |
| Volume | 119,962 |
| Website | https://www.abvcpharma.com |
| Zip | 94,538 |